Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.
申请公布号
WO2015117010(A2)
申请公布日期
2015.08.06
申请号
WO2015US13926
申请日期
2015.01.30
申请人
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
发明人
FELDMAN, ARTHUR, M.;TILLEY, DOUGLAS, G.;ZHU, WEIZHONG;KHALILI, KAMEL;KOCH, WALTER, J.